Amazon.com Inc vs Mesoblast Limited — how do they compare? Amazon.com Inc trades at $269.13 (market cap $2.94T), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: Amazon.com Inc is far larger — about 1330.3× Mesoblast Limited's market cap, and Amazon.com Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| AMZN | MESO | |
|---|---|---|
Market Cap | $2.94T | $2.21B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $284.02 | $20.96 |
52-Week Low | $198.79 | $12.88 |
Enterprise Value | $3.04T | $2.21B |
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $267.84, down 3.69% over 24 hours, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including a 17.44% net income margin and robust revenue growth to $716.92 billion in 2025. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS and AI chip expansion, fueling investor confidence.
Outlook remains positive with a consensus price target of $333.86, indicating 25% upside potential. Risks include intense competition in e-commerce and cloud services, alongside high capital expenditures. Wall Street sentiment is overwhelmingly bullish, with 89% of analysts rating it a buy, though volatility from macroeconomic factors warrants caution.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Trailing returns across standard periods
Latest headlines on both assets
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →